11.03.17
Natreon has been granted U.S., Chinese, and Japanese patents for a new bioactive isolated from Sensoril, an aqueous extract of ashwaghanda. These additional domestic and global patents cover the recent discovery of a new class of compounds, Indolealkylamino-withasteroid conjugates, and their significant acetylcholinesterase inhibitory activity.
Additionally, Natreon has been granted a U.S. patent for its Ayuric ingredient whose claims support the use of Ayuric, a standardized extract of Terminalia bellirica, for the treatment of gout, uricemia and hyperuricemia.
Finally, the Canadian patent office issued a patent for Natreon’s super antioxidant ingredient, Capros, a standardized extract of Phyllanthus emblica, which covers a composition and method to treat or prevent endothelial dysfunction.
These additional issued patents support Natreon’s focus on investing in product innovation and clinical studies to support the ingredients it brings to market.
US 9,750,778 – Issued on September 5, 2017. Title: Terminalia chebula and Terminalia bellirica for inhibition of xanthine oxidase. The allowed claims include the use of an aqueous extract of Terminalia bellirica, of a defined composition of bioactives, for the treatment of gout, uricemia and hyperuricemia. In a randomized, double-blind, placebo-controlled clinical study done on Ayuric (Clinical Pharmacology: Advances and Applications 2016:8 51–59), Natreon’s Terminilia bellirica ingredient, Ayuric was twice as effective as Termininalia chebula and 57% as effective as Febuxostat, a prescription product used to reduce uric acid levels in the blood.
CA 2,810,732 – Issued on July 18, 2017. Title: Compositions and method for improving endothelial function and cardiovascular health. The primary claim is, “use of a composition to treat or prevent endothelial dysfunction in an individual, the composition comprises an extract of pulped Phyllanthus emblica and a pharmaceutically acceptable carrier, wherein endothelial function is improved.” This patent corresponds to US 8,962,576, issued in 2015. Natreon markets this extract under the trade name Capros.
US 9,084,800 (Issued July 21, 2015), China 2440900 (Issued April 22, 2017), and
JP 6144688 (Issued May 19, 2017) – Title: Indolealkylamino-withasteroid conjugates and method of use. Natreon discovered a new class of compounds, Indolealkylamino-withasteroid conjugates, in ashwagandha (Withania somnifera) and these compounds showed significant acetylcholinesterase inhibitory activity in vitro and showed anti-Alzheimers’ activity in an ex vivo study done at Rowan University, NJ, using a pig retina model.
Additionally, Natreon has been granted a U.S. patent for its Ayuric ingredient whose claims support the use of Ayuric, a standardized extract of Terminalia bellirica, for the treatment of gout, uricemia and hyperuricemia.
Finally, the Canadian patent office issued a patent for Natreon’s super antioxidant ingredient, Capros, a standardized extract of Phyllanthus emblica, which covers a composition and method to treat or prevent endothelial dysfunction.
These additional issued patents support Natreon’s focus on investing in product innovation and clinical studies to support the ingredients it brings to market.
US 9,750,778 – Issued on September 5, 2017. Title: Terminalia chebula and Terminalia bellirica for inhibition of xanthine oxidase. The allowed claims include the use of an aqueous extract of Terminalia bellirica, of a defined composition of bioactives, for the treatment of gout, uricemia and hyperuricemia. In a randomized, double-blind, placebo-controlled clinical study done on Ayuric (Clinical Pharmacology: Advances and Applications 2016:8 51–59), Natreon’s Terminilia bellirica ingredient, Ayuric was twice as effective as Termininalia chebula and 57% as effective as Febuxostat, a prescription product used to reduce uric acid levels in the blood.
CA 2,810,732 – Issued on July 18, 2017. Title: Compositions and method for improving endothelial function and cardiovascular health. The primary claim is, “use of a composition to treat or prevent endothelial dysfunction in an individual, the composition comprises an extract of pulped Phyllanthus emblica and a pharmaceutically acceptable carrier, wherein endothelial function is improved.” This patent corresponds to US 8,962,576, issued in 2015. Natreon markets this extract under the trade name Capros.
US 9,084,800 (Issued July 21, 2015), China 2440900 (Issued April 22, 2017), and
JP 6144688 (Issued May 19, 2017) – Title: Indolealkylamino-withasteroid conjugates and method of use. Natreon discovered a new class of compounds, Indolealkylamino-withasteroid conjugates, in ashwagandha (Withania somnifera) and these compounds showed significant acetylcholinesterase inhibitory activity in vitro and showed anti-Alzheimers’ activity in an ex vivo study done at Rowan University, NJ, using a pig retina model.
